U.S. Mortgage REITs Stock News

In July 2026, Citigroup Inc. reported higher Q2 net interest income of US$17,125 million and net income of US$5,831 million year on year, alongside multiple long-dated bond offerings and detailed preferred stock dividend declarations, including plans to redeem US$1.50 billion of Series T preferred shares. While the earnings beat and increased common dividend highlight strong current profitability and capital return capacity, management’s emphasis on rising expenses and accelerated investment...

Liberty Global earnings and buyback update Liberty Global (LBTY.A) reported second quarter 2026 results that showed a smaller net loss alongside slightly lower sales, coinciding with an update on its long running multi year share repurchase program. For the second quarter ended June 30, 2026, the company reported sales of US$1,172 million compared with US$1,269.1 million in the same period a year earlier. Net loss for the quarter was US$365.1 million compared with US$2,792.9 million a year...

DENTSPLY SIRONA (XRAY) has returned to investors’ radar after recent trading data highlighted a mixed performance, with the stock trading near US$13 and returns differing significantly between the past month and the past year. See our latest analysis for DENTSPLY SIRONA. The recent move to a 1-month share price return of 18.26% and a year-to-date share price return of 15.53% suggests momentum in DENTSPLY SIRONA is improving, even though the 1-year total shareholder return declined 16.73% and...

Burke & Herbert Financial Services Corp. previously reported second-quarter 2026 results, with net interest income rising to US$93.05 million while net income fell to US$9.49 million, and the board declared a US$0.55 per share cash dividend payable on September 1, 2026. The combination of stronger net interest income but much lower earnings per share compared with a year earlier highlights pressures on overall profitability even as core lending revenue grows. Next, we’ll consider how this...

Strategy (MSTR) has drawn fresh attention after selling about $544.5 million of common stock, lifting cash reserves to roughly $3.75b while keeping its Bitcoin holdings steady and extending a five week buying pause. See our latest analysis for Strategy. Strategy’s latest move to raise equity and pause Bitcoin buying comes alongside a 1 day share price return of 7.61%, yet the stock is still down 37.23% year to date and the 1 year total shareholder return has declined 75.57%. The 3 year total...

With inflation, energy prices and central bank decisions all pulling markets in different directions, many investors are looking for growth stories that are grounded in management confidence rather than short term sentiment. Fast Growing Stocks With High Insider Ownership focus on companies where insiders have meaningful skin in the game and analysts see room for further expansion. That combination can help you concentrate on businesses where growth expectations are not just an external...

Why Incyte Stock Is Back in Focus Incyte (INCY) is back on investor watchlists after publishing full safety and efficacy results from its Phase 1/2 trial of latarcibart for von Willebrand disease and acquiring the drug’s developer, Vega Therapeutics. See our latest analysis for Incyte. Incyte’s recent clinical update and Vega Therapeutics acquisition come on the back of solid momentum, with a 90 day share price return of 21.62% and a 1 year total shareholder return of 69.43%. This indicates...

New US tariffs of 10% to 12.5% on almost all imports are reshaping the playing field for consumer stocks, putting pressure on import heavy business models while potentially opening the door for companies that make more of their goods at home. For investors, the key question is which stocks could see relatively better conditions if import costs stay elevated or volatile. This article breaks down three US consumer goods stocks from the US Import Substitute Consumer Goods Stocks screener that...

Enova International, Inc. reported past second-quarter 2026 results showing revenue of US$568.07 million and net income of US$105.06 million, alongside continued share repurchases totaling 344,645 shares for US$51.77 million under its existing buyback program. Beyond the headline growth in revenue and earnings, the combination of higher earnings per share and an active buyback underscores management’s focus on enhancing per-share financial performance. With recent results showing higher...

AST SpaceMobile (ASTS) has moved into focus after completing a US$1b senior unsecured convertible note offering due 2034, as investors also look ahead to its August 10 business update webcast. See our latest analysis for AST SpaceMobile. The recent US$1b convertible note issuance and upcoming August 10 webcast come against a mixed backdrop for AST SpaceMobile, with the share price up 3.72% over the last day and 1.52% over the past week, but down 18.42% over 30 days and 30.17% year to date...

In July 2026, Capricor Therapeutics disclosed that FDA reviewers found no statistically significant benefit for its Duchenne muscular dystrophy cell therapy Deramiocel versus placebo and raised concerns about post-hoc changes to the Phase 3 HOPE-3 trial’s statistical analysis plan, ahead of an advisory committee review. At the same time, Capricor agreed a long-term, FDA-approval‑contingent lease for a 171,000‑square‑foot San Diego headquarters that ties future manufacturing expansion...

CrowdStrike Holdings (NasdaqGS:CRWD) joined Nvidia and other partners to launch an open-source AI cybersecurity alliance. The alliance aims to build shared AI security tools and standards for defending against cyber threats. CrowdStrike also expanded its partnership with Schwarz Digits to provide sovereign EU security solutions to European enterprises. CrowdStrike operates as a cloud-based cybersecurity company focused on endpoint, identity and cloud workload protection, which ties directly...

In July 2026, Arbutus Biopharma and Genevant Sciences filed three new international patent lawsuits against Pfizer and BioNTech, seeking injunctions and monetary relief over alleged infringement of lipid nanoparticle technology used in COVID-19 mRNA vaccines across Canada and multiple European markets. These expanded legal actions add a complex layer of patent and operational risk for BioNTech, as they target core vaccine technology while Arbutus benefits from a US$178 million payment tied...

Corebridge Financial (CRBG) has drawn investor attention after expanding its Power Series of Index Annuities with a Protected Growth Benefit and preset allocation options, signaling a fresh product push in the index annuity space. See our latest analysis for Corebridge Financial. These product updates come as Corebridge Financial trades at US$31.73, with a 30-day share price return of 10.91% and a 90-day share price return of 17.82%. The 1-year total shareholder return has declined 8.5%, and...

Global inflation trends, energy price swings and shifting central bank policies are pushing investors to look more closely at companies where analysts see healthy earnings growth potential and balance sheets that can cope with bumps in the road. The Healthy high growth potential screener focuses on stocks that meet both of these tests, so you are not just chasing growth at any price. In this article you will see 3 of the best stocks from this screener, giving you a focused starting list if...

Recently, Braze (NASDAQ:BRZE) reported that its customer engagement platform continues to gain traction, with billings rising an average of 32.1% over the past year and management signaling a positive sales outlook for the next 12 months. This performance, alongside evidence of efficient customer acquisition and clear product‑market fit, suggests Braze’s business model is scaling effectively in personalized, cross‑channel marketing. Next, we’ll examine how this strong billings growth and...

Dividend announcement and upcoming earnings put Zurn Elkay Water Solutions (ZWS) in focus Zurn Elkay Water Solutions (ZWS) has declared a quarterly dividend of $0.11 per share, coinciding with rising attention ahead of its upcoming earnings announcement after the market close on Tuesday. See our latest analysis for Zurn Elkay Water Solutions. At a share price of $48.77, Zurn Elkay Water Solutions has seen a 7-day share price return of 2.03%. The 30-day and 90-day share price returns are down...

Recently, coverage on HCI Group highlighted its consistent record of beating earnings estimates and a currently positive Earnings ESP ahead of the August 6, 2026 report. This history of outperforming expectations, coupled with growing analyst optimism, has sharpened attention on how effectively HCI’s earnings quality aligns with its longer-term story. With analysts pointing to a positive Earnings ESP and bullish sentiment before the August 2026 report, we’ll examine how this affects HCI’s...

GameStop (GME) shares are back in focus after the company joined forces with Uber Eats, allowing customers to order consoles, games, accessories, and collectibles for scheduled or on demand delivery across the United States. See our latest analysis for GameStop. The Uber Eats partnership lands at a time when GameStop’s 1 day share price return of 1.65% contrasts with a 90 day share price return that is down 14.23% and a 1 year total shareholder return that is down 5.25%, pointing to pockets...

Perfect (PERF) has put up a mixed Q2 2026 scorecard, with revenue of US$16.3 million, basic EPS of US$0.013 and net income of US$1.3 million. This may prompt investors to reassess the story around growth and profitability. Over the last six reported quarters, the company has seen quarterly revenue range between about US$16.0 million and US$18.7 million, while basic EPS has moved between roughly US$0.0006 and US$0.023, offering a broad view of how earnings have tracked against a relatively...

Citizens Community Bancorp (CZWI) just posted Q2 2026 results with total revenue of US$11.8 million and basic EPS of US$0.11, alongside trailing twelve month revenue of US$58.3 million and EPS of US$1.31. Over recent quarters the company has seen revenue move from US$14.8 million in Q2 2025 to US$15.6 million in Q4 2025 and US$15.4 million in Q1 2026, while quarterly EPS ranged between US$0.32 and US$0.44 before landing at US$0.11 in the latest period. This sets up a results season in which...

With attention fixed on whether heavy AI spending at Microsoft, Amazon, Meta, and Alphabet can keep driving the S&P 500, many investors are quietly asking where else to look if enthusiasm cools. One answer is to study how fresh earnings guidance and capex trends might redirect flows toward areas such as healthcare and financials. This article breaks down three large cap stocks from our Healthcare and Financials Rotation screener that are closely tied to these shifting expectations, helping...

Why the IDE892 trial update matters for IDEAYA Biosciences stock IDEAYA Biosciences (IDYA) has moved IDE892 into Part 2 monotherapy expansion in its Phase 1/2 trial for MTAP-deleted solid tumors, including non-small cell lung cancer and pancreatic ductal adenocarcinoma. See our latest analysis for IDEAYA Biosciences. The IDE892 trial update lands at a time when IDEAYA Biosciences’ share price has shown firm momentum, with a 26.62% 90-day share price return and a 46.96% 1-year total...

Alamo Group stock has fallen 23.8% over the past year, and both its intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and its market multiples currently point to the shares trading at a discount to that intrinsic value. This raises a clear question about whether this weakness has gone too far. Alamo Group's share price decline of 23.8% over the last 12 months means investors are facing a recent loss, even as valuation tools now suggest the stock may be priced below its...